Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Screening Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

Unmet Needs in Managing MDD Interpreting Thyroid Function Tests Using Thyroid Lab Tests Testing & Screening to Optimize Men's Health

Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression, Insights from UC San Diego Health : Episode 7

Exploring the TN-10 Teplizumab Clinical Trial: Patient Demographics and Efficacy Insights

June 11, 2024

By Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP
Steven Edelman, MD

Opinion

Video

The panel reviews the TN-10 trial investigating teplizumab, focusing on patient inclusion criteria, patient outcomes, and adverse reactions.

EP: 1.Insights into the Burden of T1D: Genetic Links and Familial Considerations from UCSD Practitioners

EP: 2.The Vital Importance of Understanding and Addressing Training Gaps in Endocrinology Surrounding T1D Stages

EP: 3.The Crucial Impact of Early Intervention in Preventing T1D Stage Progression

EP: 4.Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening

EP: 5.Understanding Autoantibody Screening Tests: Methods, Interpretation, and Analysis Practicalities

EP: 6.Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact

EP: 7.Exploring the TN-10 Teplizumab Clinical Trial: Patient Demographics and Efficacy Insights

EP: 8.Teplizumab Infusion Protocol: Clinical Processes and Strategies for Infusion Access Enhancement

EP: 9.Key Insights and Practical Tips: Wisdom from UCSD Practitioners for Effective T1D Management

Recent Videos

New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time

Related Content

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease / image credit David Cherney UHN Research

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

November 7th 2024

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?

Edward J. Shahady, MD

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

October Issue of Patient Care Online Supplement is Now Live

October Issue of Patient Care Online Supplement is Now Live

Sydney Jennings

October 14th 2024

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Edward J. Shahady, MD

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

First-Ever CGM Cleared for 365-Day Use / image credit - CGM concept: ©yurii/stock.adobe.com

First-Ever CGM Cleared for 365-Day Use

September 20th 2024

The only CGM system cleared for 1 year of use in type 1 and 2 diabetes is expected to be available in the fourth quarter of this year, the manufacturers said.

Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment

Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment

Sydney Jennings

September 11th 2024

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Related Content

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease / image credit David Cherney UHN Research

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

November 7th 2024

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?

Edward J. Shahady, MD

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

October Issue of Patient Care Online Supplement is Now Live

October Issue of Patient Care Online Supplement is Now Live

Sydney Jennings

October 14th 2024

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Edward J. Shahady, MD

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

First-Ever CGM Cleared for 365-Day Use / image credit - CGM concept: ©yurii/stock.adobe.com

First-Ever CGM Cleared for 365-Day Use

September 20th 2024

The only CGM system cleared for 1 year of use in type 1 and 2 diabetes is expected to be available in the fourth quarter of this year, the manufacturers said.

Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment

Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment

Sydney Jennings

September 11th 2024

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.